New lipid-lowering drugs: an update

Area of Science:

• Cardiovascular Pharmacology
• Atherosclerosis Research
• Drug Development

Background:

• Lipid lowering is a cornerstone in managing atherosclerosis and its complications.
• Statins are primary treatments but do not fully address all dyslipidemia aspects.
• Significant unmet needs remain in comprehensive lipid management.

Purpose of the Study:

• To review emerging therapeutic compounds for dyslipidemia.
• To highlight novel targets and mechanisms beyond current lipid-lowering therapies.
• To discuss the potential of combination therapies and gene therapy for atherosclerosis.

Main Methods:

• Literature review of novel lipid-lowering agents and targets.
• Analysis of compounds for low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol.
• Examination of emerging strategies including gene therapy.

Main Results:

• Development of novel therapeutics targeting LDL-C, including thyroid mimetics, antisense oligonucleotides, and MTPIs.
• Emerging treatments for triglycerides involve PPAR agonists, MTPIs, and DGAT-1 inhibitors.
• New approaches for HDL-C include mimetic peptides, HDL delipidation, CETP inhibitors, and phospholipase inhibitors.
• Gene therapy, such as alipogene tiparvovec for LPL deficiency, is in clinical trials.

Conclusions:

• The field of lipid-lowering drugs is rapidly advancing with diverse novel compounds.
• Synergistic effects between new and established therapies offer promise for atherosclerosis treatment.
• Future treatments will likely involve a multi-targeted approach for comprehensive dyslipidemia management.